Administrative Core

行政核心

• 批准号: 10667436
• 负责人: Takahisa Kanekiyo
• 金额: $ 39.18万
• 依托单位: MAYO CLINIC JACKSONVILLE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10667436
• 关键词: Accountability; Address; Administrative Personnel; Advisory Committees; Aging; Alzheimer' s Disease; Apolipoprotein E; Biochemical; Bioinformatics; Biological Models; Biology; Biometry; Clinic; Collaborations; Communities; Complex; Data; Data Set; Dedications; Department chair; Ensure; Event; Genotype; Goals; Impaired cognition; Individual; Institution; Interdisciplinary Study; Knowledge; Knowledge Portal; LDL-Receptor Related Protein 1; Lead; Leadership; Neurology; Neurosciences; Pathogenesis; Pathogenicity; Pathway interactions; Positioning Attribute; Progress Reports; Property; Protein Isoforms; Publications; Quality Control; Reagent; Recording of previous events; Reproducibility; Research; Research Personnel; Resource Sharing; Resources; Risk; Role; Site; Structure; System; Therapeutic; United States National Institutes of Health; Universities; Washington; analytical method; data access; data management; data sharing; design; experience; innovation; medical schools; meetings; nervous system disorder; novel; programs; protective effect; research in practice; responsible research conduct; sharing platform; symposium; synergism; web portal; web site

PROJECT SUMMARY (APOE U19 Core A: Administrative Core) The Administrative Core will lead this U19 project by providing administrative, fiscal, and scientific oversight and promoting synergy of all Cores and Projects to address the ApoE Cascade Hypothesis. Core A will serve several functions to facilitate the scientific objectives and rigor of this U19. It will also serve the broader scientific community by sharing knowledge, resources, and datasets through a web portal and by promoting collaboration through an annual ApoE Symposium. Core A will cooperate fully with NIA initiatives with a dedicated leadership team and administrative personnel with relevant experience. As the Co-PIs of this U19 project and Co-Leaders of Core A, Drs. Guojun Bu (Mayo Clinic Jacksonville) and David Holtzman (Washington University in St. Louis) are recognized leaders in the apoE field; each has more than 25 years of experience studying apoE and apoE receptors as they relate to the pathogenesis of AD and other aging- related conditions. Drs. Bu and Holtzman have a long history of collaboration and are well positioned to share leadership roles for this U19 program at the two coordinating institutions. They also have strong leadership experience each serving as a Department Chair and an Associate Director of Alzheimer’s Disease Research Center at their respective institution. Together with Dr. Alison Goate, who will serve as the Site-PI at Icahn School of Medicine at Mount Sinai, they will ensure integration and synergy across the U19 by pursuing the following aims: Aim 1: Provide administrative structure, fiscal oversight, and site coordination for the U19 program. Aim 2: Assume responsibility for the quality control of the U19 activities by ensuring responsible conduct of research, rigor, and reproducibility of research practices, and by ensuring compliance with all internal and external regulatory requirements. Promote and track open-access publications and facilitate submission of progress reports to NIH. Aim 3: Promote the scientific direction and integration of the U19 components by organizing meetings of the Internal Steering Committee and External Advisory Committee. Aim 4: Develop and maintain an apoE website what will serve as knowledge portal, and resource and data sharing platform. Aim 5: Organize Annual ApoE Symposium for U19 investigators as well as the broader scientific community to interact and share research findings. These innovative aims will ensure that the robust and rigorous efforts by the U19 team investigators will lead to new discoveries to inform therapeutic strategies.

项目摘要（APOE U19 核心 A：管理核心） 行政核心将通过提供行政、财政和科学监督来领导这个 U19 项目 促进所有核心和项目的协同作用，以解决 ApoE 级联假设 核心 A 将发挥作用。 促进本次 U19 科学目标和严谨性的多项功能还将服务于更广泛的领域。 科学界通过门户网站共享知识、资源和数据集并促进 Core A 将通过年度 ApoE 研讨会与 NIA 倡议进行全面合作。 作为本次U19的联合PI，敬业的领导团队和具有相关经验的管理人员。 项目和核心 A 联合领导者，Guojun Bu 博士（梅奥诊所杰克逊维尔）和 David Holtzman （圣路易斯华盛顿大学）是 apoE 领域公认的领导者，每个人都有超过 25 年的研究经验； 研究 apoE 和 apoE 受体的经验，因为它们与 AD 和其他衰老的发病机制有关 Bu 博士和 Holtzman 有着悠久的合作历史，并且能够很好地分享。 两个协调机构对该 U19 计划的领导作用 他们也具有强有力的领导作用。 担任阿尔茨海默病研究系主任和副主任的经历 与艾莉森·戈特 (Alison Goate) 博士一起在各自的机构担任中心，她将担任伊坎的站点 PI。 西奈山医学院，他们将通过追求以下目标来确保 U19 的整合和协同作用 以下目标： 目标 1：为 U19 提供行政结构、财政监督和现场协调 目标 2：通过确保负责来承担 U19 活动的质量控制责任。 研究的进行、研究实践的严谨性和可重复性，并确保遵守所有 促进和跟踪开放获取出版物并促进内部和外部监管要求。 向 NIH 提交进展报告 目标 3：促进 U19 的科学方向和整合。 组织内部指导委员会和外部咨询委员会的会议。 4：开发和维护apoE网站，作为知识门户、资源和数据共享 目标 5：为 U19 研究人员以及更广泛的科学界组织年度 ApoE 研讨会。 这些创新目标将确保社区的互动和分享研究成果。 U19 团队研究人员的不懈努力将带来治疗信息策略的新发现。